85%Confidence
0Views
FDASource
2026-03-05Date
Summary
Repeat testosterone recall for Asteria Health indicates persistent quality control problems across multiple product strengths. This suggests systemic manufacturing issues that could threaten the company's viability.
Actionable: Avoid investment in Asteria Health until they demonstrate comprehensive quality system improvements and regulatory compliance.
AI Confidence: 85%
Data Points
firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productTestosterone, 200 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-1200-43.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now